Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
1. |
ECCT/14/11/01 | ZEBOV Trial A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult… read more |
Principal Investigator(s) 1. Philip Bejon 2. Patricia Njuguna Site(s) in Kenya KEMRI Wellcome Trust Research Programme |
View |
2. |
ECCT/22/09/03 | SINGLE DOSE VERSUS EXTENDED DO EFFECTIVENESS OFSINGLE-DOSE ANTIBIOTIC USE IN ELECTIVE CAESAREANSECTION IN PREVENTION OF SURGICAL SITE INFECTION AT JARAMOGI OGINGA… read more |
Principal Investigator(s) 1. STEVEN ODHIAMBO JUMA Site(s) in Kenya JARAMOGI OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL |
View |
3. |
ECCT/23/09/02 | CROSSWALK Acute (A) A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE… read more |
Principal Investigator(s) 1. Doreen Terry Karimi Site(s) in Kenya Gertrudes Childrens Hospital |
View |
4. |
ECCT/20/07/02 | RV 460 HIV Vaccine Trial A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenicity of Priming with Env-C Plasmid DNA Vaccine Alone, with Different… read more |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI/US MRDA-A/K, KERICHO |
View |
5. |
ECCT/20/11/02 |
IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults (IAVI C100) |
Principal Investigator(s) 1. Nelly Mugo Site(s) in Kenya 1. Partners in Health Research and Development (PHRD) – CCR-KEMRI (Kiambu county) 2. Kenya AIDS… read more |
View |